Abstract

Objective. Several studies showed better outcome in adolescents and young adults with acute lymphoblastic leukemia (ALL) treated with pediatrics protocols than similarly aged patients treated with adults protocols, while other studies showed similar outcome of both protocols. We conducted this study to compare the outcome of our pediatrics and adults therapeutic protocols in treatment of adolescents ALL. Patients and Methods. We retrospectively reviewed files of 86 consecutive adolescent ALL patients aged 15–18 years who attended to outpatients clinic from January 2003 to January 2010. 32 out of 86 were treated with pediatrics adopted BFM 90 high risk protocol while 54 were treated with adults adopted BFM protocol. We analyzed the effect of different treatment protocols on achieving complete remission (CR), disease-free survival (DFS), and overall survival (OS). Results. The 2 patients groups have almost similar characteristics. The CR was significantly higher in pediatrics protocol 96% versus 89% (P = 0.001). Despite the fact that the toxicity profiles were higher in pediatrics protocol, they were tolerable. Moreover, the pediatrics protocol resulted in superior outcome in EFS 67% versus 39% (P = 0.001), DFS 65% versus 41% (P = 0.000), and OS 67% versus 45% (P = 0.000). Conclusion. Our study's findings recommend using intensified pediatrics inspired protocol to treat adolescents with acute lymphoblastic leukemia.

Highlights

  • Acute lymphoblastic leukemia (ALL) remains one of the most challenging adults’ hematological malignancies [1]

  • Five-year event-free survival (EFS) for AYA treated with pediatric regimens ranges from 64% to 69% while in adult regimen it ranges from 34% to 49% [17,18,19,20]

  • The B lineage was accounted for 81% in pediatrics protocol group and 82% in adults protocol group whereas the T lineage was accounted for 19% in the pediatrics protocols group and 18% in the adults one (P = 0.091)

Read more

Summary

Introduction

Acute lymphoblastic leukemia (ALL) remains one of the most challenging adults’ hematological malignancies [1]. The use of multiagent chemotherapy regimens for the treatment of acute lymphoblastic leukemia (ALL) is considered as a cancer success story in the pediatric setting [2], which have offered patients who once had a dismal prognosis a cure rate that approaches or exceeds 90% [3, 4]. Retrospective studies focusing on patient’s age 15 to 21 years showed that “Adolescents and Young Adults” (AYA) treated with adults ALL protocols have poorer outcomes than aged patients treated with pediatric protocols [8,9,10,11,12,13,14,15,16]. Five-year event-free survival (EFS) for AYA treated with pediatric regimens ranges from 64% to 69% while in adult regimen it ranges from 34% to 49% [17,18,19,20]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call